What adjuvant therapy would you offer following adjuvant chemotherapy for a patient with Stage III lung adenocarcinoma with an atypical EGFR mutation such as EGFR L861R?

Topics: Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • EGFR+

Would you offer adjuvant atezolizumab, osimertinib, or neither? Both IMpower010 and ADAURA only had patients with EGFR exon 19 deletion or L858R mutations.

Answer from: Medical Oncologist at Academic Institution

Mutations at position 861 (most commonly L861Q) have been described, occurring in approximately 2% of all EGFR-mutant patients [Mitsudomi and Yatabe, PMID 19922469]. These mutations are considered partially sensitizing to afatinib based on a post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung ...

Comments

Medical Oncologist at Blue Ridge Cancer Care
Thank you very much Dr. @Tejas Patil for your...

Medical Oncologist at Onc San Antonio
Dr. @Tejas Patil, would you offer adjuvant Atezo i...

Medical Oncologist at University of Colorado
I would not offer adjuvant atezolizumab to EGFRm N...

Medical Oncologist at Onc San Antonio
Thank you Dr. @Patil for your insight and I a...

Medical Oncologist at Clinical Instructor
Yes, Dr. @Navneet Mittal, a common scenario and a ...

Medical Oncologist at University of Colorado
There is data on EGFRm NSCLC who received durvalum...

Medical Oncologist at Onc San Antonio
Thank you Dr. @Anthony Bejjani for directing me to...

Related Questions